MDM2 and acute myeloid leukemia: Clinical trials on MDM2 inhibitors are ongoing in acute myeloid leukemia (AML) (NCT02319369, NCT03634228), soft tissue sarcoma (NCT03217266), malignant salivary gland carcinoma (NCT03781986), pediatric cancers (NCT03654716) and small cell lung cancer (NCT04022876) (51, 52).